GRAMMY Museum® Grant Program Awards $200,000 for Music Research and Sound Preservation
Article content
LOS ANGELES — The GRAMMY Museum ® Grant Program announced today that $200,000 in grants will be awarded to 15 recipients in the United States to help facilitate a range of research on a variety of subjects, as well as support a number of archiving and preservation programs.
Article content
'The GRAMMY Museum and Recording Academy ® have continued their partnership to provide fundamental funding for music research and preservation projects across the United States and Canada. We are incredibly inspired by this year's recipients and what they set to accomplish,' said Michael Sticka, President/CEO of the GRAMMY Museum. 'Our mission is to lead in fostering a world where a shared passion for music fuels curiosity, creativity and community. We are honored to support these remarkable projects that continue to shape the future of music, science and technology.'
Article content
Article content
Generously funded by the Recording Academy, the GRAMMY Museum Grant Program provides funding annually to organizations and individuals to support efforts that advance the archiving and preservation of the recorded sound heritage of the Americas for future generations, in addition to research projects related to the impact of music on the human condition. In 2008, the GRAMMY Museum Grant Program expanded its categories to include assistance grants for individuals and small to mid-sized organizations to aid collections held by individuals and organizations that may not have access to the expertise needed to create a preservation plan. The assistance planning process, which may include inventorying and stabilizing a collection, articulates the steps to be taken to ultimately archive recorded sound materials for future generations. This year marks the 37th year of the program.
Article content
More information about the program can be found at www.grammymuseum.org.
Article content
CERVO Brain Research Center — Quebec City, QC
Awarded: $20,000
Their goal is to uncover how choir singing impacts communication (voice, articulation, listening) and auditory cognition in older adults, supporting healthy aging through a randomized training study. We further explore neurobiological mechanisms underlying these changes via multimodal brain imaging. This project aims to inform community choirs and music-based interventions, aligning with the foundation's mission to enhance quality of life through music.
Article content
Jewish Rehabilitation Hospital – CISSS Laval — Laval, QC
Awarded: $19,500
Stroke typically leads to persistent deficits in arm and hand function. This project will examine the feasibility, acceptability and preliminary effectiveness of a 6-week piano training intervention aimed at improving manual dexterity and the functional use of the arm and hand. For the first time, such intervention will be delivered as part of a home-based, early, and intensive rehabilitation program for individuals with stroke.
Article content
New York University — New York, NY
Awarded: $9,000
Many people struggle with speech-language disorders due to developmental issues or brain injuries. Although music therapy can help these individuals regain speech functions, its effectiveness varies because we don't fully understand the underlying brain mechanisms. By combining neuroimaging and machine learning, this study will explore how the brain can 'bypass' damaged speech-language networks by leveraging musical networks to enhance communication.
Article content
Article content
University of South Florida — Tampa, FL
Awarded: $9,000
This randomized trial will examine the effects of a novel woodwind program on neural responses and respiration function in adults 50+ with Long-term COVID (LTC). Adults will complete measures of cognitive processing (EEG) and respiration function (spirometer), pre and post-10 weeks of either Nuvo jsax lessons or an attentional control task. We predict that a woodwind program will enhance cognitive processing and respiration function in adults with LTC.
Article content
University of Toronto — Toronto, ON
Awarded: $20,000
Rhythmic Auditory Stimulation (RAS ®) uses rhythmic sound cues to help people with Parkinson's disease (PD) start and maintain stable movement. This project is the first to examine how these cues impact brain chemistry in PD, revealing the brain's response to these cues. Their findings could improve the use of RAS as part of PD care, refining clinical applications that work alongside standard medication to support movement and enhance quality of life in PD.
Article content
Lex Gillespie — Washington, D.C.
Awarded: $5,000
The project will preserve 75 interviews from the 10-hour Peabody Award-winning public radio series, 'Whole Lotta Shakin'.' It tells the story of rockabilly, the exciting 1950s mix of blues, gospel and country that is the cornerstone of rock and roll. This diverse collection features singers, musicians, producers, disc jockeys, and record company owners. The goal: to digitize these decaying recordings for use by scholars, content providers and the public.
Article content
Memphis Listening Lab — Memphis, TN
Awarded: $5,000
GRAMMY Museum Preservation Assistance funding will enable the Memphis Listening Lab (MLL) to hire an expert consultant to conduct a Preservation Assessment of MLL's extensive collection of recorded music. The consultant will be drawn from the GRAMMY Museum's list of recommended experts and will provide MLL with a written report detailing their observations and recommendations for preserving MLL's collection, which is freely accessible to the public.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
a day ago
- Cision Canada
Health Canada Approves Dual Immunotherapy OPDIVO® Plus YERVOY® for Colorectal and Liver Cancers Français
MONTREAL, Aug. 19, 2025 /CNW/ - Bristol Myers Squibb Canada (BMS) today announced that Health Canada has approved OPDIVO ® (nivolumab) in combination with YERVOY ® (ipilimumab) for the first-line treatment of adult patients with: unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), and unresectable or advanced hepatocellular carcinoma (HCC) 1. This dual immunotherapy regimen offers a new first-line treatment approach for two challenging gastrointestinal cancers, supported by two pivotal Phase 3 trials: CheckMate-8HW in CRC which demonstrated improvement in progression-free survival, and CheckMate-9DW in HCC which showed improvements in survival—each compared to existing standard therapies 1. "Although we've seen progress, microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer is clinically complex, particularly in the first-line setting where there remains an ongoing need for additional treatments," said Vancouver-based medical oncologist, Dr. Sharlene Gill. "The approval of OPDIVO ® plus YERVOY ®, supported by CheckMate-8HW, the largest phase 3 immunotherapy trial to date in this population, offers a well-studied and very clinically meaningful option for patients and clinicians treating this distinct molecular subtype of colorectal cancer." Calgary-based medical oncologist, Dr. Hatim Karachiwala added,"For patients with unresectable or advanced hepatocellular carcinoma improving outcomes continues to be a critical priority. Data from CheckMate-9DW provides useful insights into how the OPDIVO ® plus YERVOY ® dual immunotherapy strategy might be considered as part of the initial treatment approach." BMS introduced immunotherapy in Canada in 2012 with the approval of YERVOY ®, ushering in a new era of cancer treatment providing an important option for patients with advanced cancers. The 2016 approval of the first dual immunotherapy regimen—YERVOY ® plus OPDIVO ® —further expanded this foundation. These latest indications further expand the reach of the combination to include MSI-H/dMMR colorectal and liver cancer patients. Immunotherapy Advances Welcomed by Patient Groups "In a country where colorectal cancer remains one of the most commonly diagnosed cancers and a leading cause of cancer death for both men and women 2, this news represents a much-needed advancement," said Barry Dr. Stein, President and CEO, Colorectal Cancer Canada. "This dual immunotherapy approach provides eligible patients and their care teams with a new, clinically validated strategy to take action early in the treatment journey." Filomena Servidio-Italiano, President and CEO, Colorectal Cancer Resource & Action Network (CCRAN), added, "These approvals mark important progress for both the colorectal and liver cancer communities. For those facing aggressive disease, time matters. Expanding access to first-line immunotherapy—particularly with combination strategies that enhance the immune system engagement—responds to an important unmet need." "Making up approximately 75% all primary liver cancer cases 3, hepatocellular carcinoma has a significant impact on patients across the country," said Jennifer Nebesky, President and CEO, Liver Canada. "In 2024, liver cancer was projected to be diagnosed in 4,700 Canadians, with 3,700 deaths 4 —figures that speak to the need for continued progress in improving care. The approval of OPDIVO ® plus YERVOY ® as a first-line treatment provides renewed hope and a new path forward for patients and clinicians alike." In the CheckMake-8HW trial, OPDIVO ® plus YERVOY ® reduced the risk of disease progression or death by 79% compared to chemotherapy in the first-line treatment of MSI-H/dMMR metastatic colorectal cancer. In advanced hepatocellular carcinoma, the CheckMate-9DW trial showed the combination delivered a statistically significant overall survival benefit compared to tyrosine kinase inhibitors. These results highlight the potential of dual immunotherapy to drive meaningful change in early treatment across both cancers. "These approvals underscore our continued focus on advancing immunotherapy where it can make a meaningful difference," said Elaine Phillips, General Manager, Bristol Myers Squibb Canada. "By introducing OPDIVO ® plus YERVOY ® as a first-line treatment option for these two distinct and challenging gastrointestinal cancers, we are expanding access to a dual immunotherapy approach in areas with significant unmet need. This milestone reflects our commitment to delivering innovative science with real-world impact." Clinical Trials Overview OPDIVO ® (nivolumab), in combination with YERVOY ® (ipilimumab), was evaluated in two pivotal Phase 3 trials—CheckMate-8HW and CheckMate-9DW—supporting its first-line use in MSI-H/dMMR colorectal and liver cancers. CheckMate-8HW is a global, randomized, open-label Phase 3 trial that enrolled 839 patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC). The trial included an evaluation of OPDIVO ® plus YERVOY ® (n=202) versus standard-of-care chemotherapy (with or without bevacizumab or cetuximab) (n=101). The OPDIVO ® plus YERVOY ® versus investigator's choice chemotherapy with/without bevacizumab or cetuximab arm of the trial showed that the combination regimen reduced the risk of cancer progression or death by 79% compared to chemotherapy in centrally confirmed MSI-H/dMMR mCRC first-line patients (HR 0.21; 95% CI: 0.14-0.32; P<0.0001). After a median follow-up of 31.5 months, median progression-free survival (PFS) was not reached with OPDIVO ® plus YERVOY ® (95% CI: 38.4-NE) compared to 5.9 months with chemotherapy (95% CI: 4.4-7.8). Kaplan-Meier curves showed early and sustained separation starting at three months, with PFS rates of 79% vs. 21% at 12 months and 72% vs. 14% at 24 months, respectively. CheckMate-9DW is a global, randomized, open-label Phase 3 trial that enrolled 668 patients with unresectable or advanced hepatocellular carcinoma (HCC) who had not received prior systemic therapy. Patients were randomized to receive OPDIVO ® plus YERVOY ® (n=335) or investigator's choice of lenvatinib or sorafenib monotherapy (n = 333). The dual immunotherapy regimen consisted of OPDIVO ® 1 mg/kg plus YERVOY ® 3 mg/kg every three weeks for up to four doses, followed by OPDIVO ® monotherapy 480 mg every four weeks. The trial demonstrated a statistically significant improvement in overall survival (OS): median OS was 23.7 months with OPDIVO ® plus YERVOY ® versus 20.6 months with lenvatinib/sorafenib (HR 0.79; 95% CI: 0.65–0.96; p = 0.0180). The overall response rate (ORR) was 36.1% vs. 13.2% (p < 0.0001), with complete responses in 6.9% of patients receiving dual immunotherapy. Median duration of response was 30.4 months vs.12.9 months. In both trials, the safety profile of OPDIVO ® plus YERVOY ® was consistent with the known class effects of PD-1 and CTLA-4 inhibitors. Immune-mediated adverse events were generally manageable with established treatment algorithms. For more information, including prescribing and safety information related to the new indications, please consult the Canadian product monograph for OPDIVO ® here. About Bristol Myers Squibb Canada Co. Bristol Myers Squibb Canada Co. is an indirect wholly-owned subsidiary of Bristol Myers Squibb Company, a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Bristol Myers Squibb Canada Co. employs close to 300 people across the country. For more information, please visit ____________ SOURCE Bristol-Myers Squibb Canada
Cision Canada
a day ago
- Cision Canada
Cepheid Receives Health Canada Licence for Xpert® HCV VL Fingerstick
Detection and quantitation of Hepatitis C virus (HCV) in about an hour SUNNYVALE, Calif. , Aug. 19, 2025 /CNW/ -- Cepheid today announced that Health Canada has issued Cepheid a medical device licence for Xpert ® HCV VL Fingerstick, an HCV RNA test that detects and quantifies HCV directly from a drop of blood, simplifying the diagnostic pathways to speed up linkage to care and monitoring sustained virological response. Xpert HCV VL Fingerstick test is performed on the GeneXpert ® system. There is no vaccine for hepatitis C, but it can be treated and cured with antiviral medications. The Health Infobase estimates that over 200,000 people are living with chronic hepatitis C in Canada. 1 Globally, more than half of people with HCV do not know that they have the virus. "Timely diagnosis is key to identifying and treating people with hepatitis C. Point-of-care tests allow us to diagnose people wherever they are, without necessarily needing them to come to traditional health care facilities. This can be hugely impactful, particularly for those who do not have equitable access to health care, such as people who use drugs and people in remote settings," said Dr. Jordan Feld, Director of the Toronto Centre for Liver Disease and Professor of Medicine at the University of Toronto. "To reach the World Health Organization's goal of eliminating HCV by 2030, we need to find and diagnose those living with HCV and get them access to care and treatment. Point-of-care tests make that much more feasible." "This simple to use test detects the full range of known HCV genotypes in about an hour and can be performed on a small volume of blood collected via fingerstick," said Vitor Rocha, President of Cepheid. "This is the first HCV RNA detection and quantification technology sensitive enough for active case finding at the point of care in Canada. This enables diagnosis of HCV and facilitates timely linkage to care within a single clinic visit — and with this, the potential for treating more people with HCV." The test is designed for use on Cepheid's GeneXpert system which provides simple, reference lab quality PCR testing on location in laboratory environments at medical centers and hospitals or in community health clinics and physician offices. Xpert® HCV VL Fingerstick will begin shipping to customers in Canada in August 2025. Visit for more information. 1. Accessed July 2025 About Cepheid Based in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company that is an operating company within Danaher Corporation's Diagnostics platform. Cepheid is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit IVD. In Vitro Diagnostic Medical Device. May not be available in all countries For Cepheid Media Inquiries: Darwa Peterson [email protected]
Cision Canada
6 days ago
- Cision Canada
U.S. Military Study Identifies TITAN CSR® Retractor as Top Surgical Retractor for Deployed Trauma Care
Department of Defense–funded evaluation at MHSRS 2025 finds TITAN CSR® retractor delivers the greatest abdominal exposure, fastest setup, and highest overall surgeon satisfaction among systems tested. SAN ANTONIO, Aug. 14, 2025 /CNW/ -- Advanced Surgical Retractor Systems, Inc. (ASR Systems) announced today that its flagship product, the TITAN CSR® retractor, distributed by Keir Surgical in Canada, was identified as the top-performing retractor system in a Department of Defense–funded study evaluating surgical retraction platforms for forward-deployed surgical teams.
